Purchase of Tandem Mass Spectrometer (TRIPLE QTRAP 6500+) and Associated Maintenance
A Contract Award Notice
by NHS WALES SHARED SERVICES PARTNERSHIP-PROCUREMENT SERVICES (HOSTED BY VELINDRE UNIVERSITY NHS TRUST)
- Source
- Find a Tender
- Type
- Contract (Goods)
- Duration
- not specified
- Value
- £325K
- Sector
- INDUSTRIAL
- Published
- 16 Feb 2021
- Delivery
- not specified
- Deadline
- n/a
Concepts
Location
Cardiff and Vale of Glamorgan: University Hospital of Wales
1 buyer
1 supplier
- Ab Sciex Cheshire
Description
Cardiff & Value UHB are looking to purchase a TRIPLE QTRAP 6500+ from AB Sciex, the value is inclusive of 3 years maintenance post 12 months warranty.
Total Quantity or Scope
Cardiff & Vale UHB intends to purchase a TRIPLE QTRAP 6500+ system to improve and increase the performance of a multitude of assays including plasma/ urine metadrenalines and 17-hydroxy Progesterone in serum, saliva and bloodspots, unattended autosampling and continuous running of samples in a 24 hour period. This equipment will be compatible with existing AB Sciex platforms. The purchase will include associated maintenance service plan.
Award Detail
1 | Ab Sciex (Cheshire)
|
CPV Codes
- 38433100 - Mass spectrometer
Legal Justification
There is a requirement for a triple quadrupole tandem mass spectrometer fitted with an interchangeable ionisation source. It must have a liquid chromatography unit with an automated sample introduction. The instrument must be able to perform a multitude of assays including plasma/ urine metadrenalines and 17-hydroxy Progesterone in serum, saliva and bloodspots. Unattended autosampling and continuous running of samples in a 24 hour period should be possible. A computer system should be supplied capable of running the tandem mass spectrometer and sampling system, as well as analysing the mass spectral data to produce results in a reportable format. The laboratory currently operates other AB Sciex instruments sensitive enough for measurement of plasma metadrenalines/salivary samples. To minimise clinical disruption it is imperative that the new instrument would replicate the existing system ensuring compatibility and interfacing whilst also allowing for further developments. This will mean current methods will be able to be transferred across with no new development work required and reduce staff training to use and maintain the instruments. This will also reduce the implementation time of the new system into our clinical service and ensure we provide a robust service for our clinical users. Training requirements will be reduced which will allow allocation of staff time to further development, future-proofing our clinical service.
Other Information
** PREVIEW NOTICE, please check Find a Tender for full details. ** (WA Ref:108232)
Reference
- ocds-h6vhtk-02937c
- FTS 003093-2021